Subscribe
22 September 2017Americas

Video interview: Allen & Overy on CRISPR evolution

To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Video interview: Allen & Overy on the UPC and CRISPR
19 September 2017   The Unified Patent Court is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.
article
Video interview: Canada prepares for PTE system
5 September 2017   The development of Canada’s exclusivity framework was the focus of a roundtable at Life Sciences Patent Network North America, hosted by LSPR in Boston.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
Video interview: Allen & Overy on the UPC and CRISPR
19 September 2017   The Unified Patent Court is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.
article
Video interview: Canada prepares for PTE system
5 September 2017   The development of Canada’s exclusivity framework was the focus of a roundtable at Life Sciences Patent Network North America, hosted by LSPR in Boston.

More on this story

Americas
Video interview: Allen & Overy on the UPC and CRISPR
19 September 2017   The Unified Patent Court is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.
article
Video interview: Canada prepares for PTE system
5 September 2017   The development of Canada’s exclusivity framework was the focus of a roundtable at Life Sciences Patent Network North America, hosted by LSPR in Boston.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages